In Vitro Growth Inhibition of Human Small Cell Lung Cancer by Physalaemin

G. Bepler, D. N. Carney, A. F. Gazdar, J. D. Minna

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Production and secretion of neuroendocrine peptides by small cell lung cancer (SCLC) has been detected in the past years. Most recently the role of bombesin as an autocrine/paracrine growth modifier has been demonstrated. We used the soft agarose clonogenic assay to evaluate the influence of other neuroendocrine peptides on the in vitro proliferation of SCLC cell lines. Neuroendocrine peptides tested were adrenocorticotropic hormone, arginine vasopressin, calcitonin, glucagon, kassinin, neurotensin, physalaemin, somatostatin, and substance P. Experiments were carried out in serum-free and serum-supplemented media with and without serum-free incubation periods. Our results indicated that the amphibian undecapeptide physalaemin inhibits the clonal and mass culture growth of SCLC cell lines at picomolar concentrations. All other neuroendocrine peptides failed to influence SCLC growth in the test systems used. These results suggest a growth regulating effect of physalaemin and a potential new form of neuroendocrine peptide therapy for SCLC.

Original languageEnglish (US)
Pages (from-to)2371-2375
Number of pages5
JournalCancer research
Issue number9
StatePublished - May 1 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'In Vitro Growth Inhibition of Human Small Cell Lung Cancer by Physalaemin'. Together they form a unique fingerprint.

Cite this